Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 11/20 | 0.65 |
| ▸ | AHR | P35869 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8381353 | 0.88 | TRPA1 (0.68) | TRPA1AHRMAPTMEN1KMT2A | |
| SCHEMBL19885494 | 0.80 | AHR (0.63) | TRPA1AHRMAPTMEN1KMT2A | |
| SCHEMBL3526060 | 0.79 | TRPA1 (0.65) | TRPA1AHRMAPTMEN1KMT2A | |
| SCHEMBL8133280 | 0.79 | TRPA1 (0.65) | TRPA1MAPTMEN1KMT2AHTT | |
| Dibenzo[B,F][1,4]Oxazepine SCHEMBL123289 | 0.79 | TRPA1 (1.00) | TRPA1MAPTMEN1KMT2AHTT | |
| SCHEMBL2307384 | 0.78 | TRPA1 (0.57) | TRPA1AHRMAPTMEN1KMT2A | |
| Dibenzo[B,F][1,4]Oxazepine SCHEMBL30601896 | 0.77 | TRPA1 (0.96) | TRPA1MAPTMEN1KMT2AHTT | |
| SCHEMBL25215566 | 0.76 | TRPA1 (0.73) | TRPA1MAPTMEN1KMT2AHTT | |
| SCHEMBL30311105 | 0.76 | TRPA1 (0.73) | TRPA1MAPTMEN1KMT2AHTT | |
| SCHEMBL3525317 | 0.76 | AHR (0.44) | TRPA1AHRMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737136-B2 | Non-steroidal progesterone receptor modulators | N.V. ORGANON (NL) | 2010-06-15 | — | — | US | disclosed |
| US-7737136-B2 | Non-steroidal progesterone receptor modulators | N.V. ORGANON (NL) | 2010-06-15 | — | — | US | disclosed |
| US-7737136-B2 | Non-steroidal progesterone receptor modulators | N.V. ORGANON (NL) | 2010-06-15 | — | — | US | disclosed |
| EP-1495030-B1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | ORGANON NV (NL) | 2008-08-13 | — | — | EP | disclosed |
| US-20050171087-A1 | Non-steroidal progesterone receptor modulators | MERCK SHARP & DOHME B.V. (NL) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171087-A1 | Non-steroidal progesterone receptor modulators | PGR, PGRMC1, PGRMC2 | TRPA1 757/4885AHR 1216/4885MAPT 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.